Top Markets
Coin of the day
Pharvaris N.V. Pharvaris N.V.

Pharvaris N.V.

PHVS
Rangering i aksjer #5575
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the... Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Aksjekurs
$36.98
Sist synkronisert: 2026-08-26
Markedsverdi
$2.58B
Endring (1 dag)
-0.67%
Endring (1 år)
55.51%
Land
NL
Handel Pharvaris N.V. (PHVS)

Kategori

EPS for Pharvaris N.V. (PHVS)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Pharvaris N.V. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Pharvaris N.V. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH